154 related articles for article (PubMed ID: 35217310)
1. Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.
Hargreaves R; Harrison CN; McLornan DP
Curr Res Transl Med; 2022 Jul; 70(3):103338. PubMed ID: 35217310
[TBL] [Abstract][Full Text] [Related]
2. How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
McLornan DP; Hargreaves R; Hernández-Boluda JC; Harrison CN
Br J Haematol; 2022 May; 197(4):407-416. PubMed ID: 35191542
[TBL] [Abstract][Full Text] [Related]
3. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.
Pizzi M; Croci GA; Ruggeri M; Tabano S; Dei Tos AP; Sabattini E; Gianelli U
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830822
[TBL] [Abstract][Full Text] [Related]
4. Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
McLornan DP; Malpassuti V; Lippinkhof-Kozijn A; Potter V; Beelen D; Bunjes D; Sengeloev H; Radujkovic A; Passweg J; Chalandon Y; Kröger N; Wulf GG; Johansson JE; Ciceri F; Bornhäuser M; Holler E; Guffroy B; Martin S; Neubauer A; Gramatski M; Robin M; Iacobelli S; Hayden P; Hernández Boluda JC; Czerw T; Yakoub-Agha I
Br J Haematol; 2020 Aug; 190(3):437-441. PubMed ID: 32108327
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
7. Approach to MPN Symptom Assessment.
Geyer H; Mesa RA
Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Deschamps P; Moonim M; Radia D; Curto-Garcia N; Woodley C; Bassiony S; O'Sullivan J; Harrington P; Raj K; Francis Y; Kordasti S; Ali S; Harrison CN; McLornan DP
Br J Haematol; 2021 May; 193(4):792-797. PubMed ID: 33751548
[TBL] [Abstract][Full Text] [Related]
9. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.
Koren-Michowitz M; Lavi N; Ellis MH; Vannucchi AM; Mesa R; Harrison CN
Ann Hematol; 2017 Jan; 96(1):87-92. PubMed ID: 27734130
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
13. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
14. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
[TBL] [Abstract][Full Text] [Related]
15. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
[TBL] [Abstract][Full Text] [Related]
16. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
17. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
18. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
19. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
20. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
Gowin K; Langlais BT; Kosiorek HE; Dueck A; Millstine D; Huberty J; Eckert R; Mesa RA
Cancer Med; 2020 Dec; 9(24):9445-9453. PubMed ID: 33140580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
